Debus 2006.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 385, non‐small cell lung cancer (stage III, primarily inoperable); concomitant treatment: radiochemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 12‐14 g/dL, in 11/2003 reduced to 12‐13 g/dL planned ESA duration = during chemotherapy and radiotherapy
Outcomes	Primary: 2‐year‐survival rate; secondary: tumor response, QoL, tolerance to epoetin alpha, Hb change, transfusion, safety
Notes	study number = 83322
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	randomization code provided by OrthoBiothech
Allocation concealment?	Unclear risk	assigned envelopes, sequentially numbered, but it is unclear whether they were sealed and opaque